Moderna: mRNA Vaccine Cold Chain Transport Cases
Challenge
Moderna develops mRNA vaccines for COVID-19, RSV, and flu. They need cases for mRNA vaccine transport at -20°C ± 5°C to 50+ countries. Cases must: (1) maintain -20°C for 72h, (2) meet IATA Dangerous Goods for dry ice, (3) protect $10,000+ vaccine shipments, (4) integrate with Moderna's track-and-trace, (5) be reusable 100+ cycles.
Solution
KeXinMaterials provided pharma-grade cases with: (1) IATA-compliant PCM cooling for -20°C ± 5°C / 72h, (2) PP copolymer with insulation, (3) custom foam for mRNA vials, dry ice containment, temperature loggers, (4) serialized QR + Moderna track-and-trace, (5) 100+ cycle rating. Custom foam for vaccine vials, dry ice packs, Sensitech TempTale loggers.
Result
2,200 cases deployed across 50+ countries. 18 months zero temperature excursion. 100% IATA compliance. Moderna standardized KeXinMaterials as a qualified mRNA cold chain case vendor.
Client Testimonial
Moderna's mRNA vaccines require -20°C ± 5°C cold chain integrity across 50+ countries. KeXinMaterials cases have proven IATA compliance and 72-hour temperature stability. The 100+ cycle reusability supports our ESG goals. They're our standard mRNA cold chain case. — Moderna Global Logistics Director
— Moderna, Inc.
Project Duration
Ongoing (3-year MSA)
Total Value
$1,400,000
Industry
Biotech / Pharmaceutical
Related Resources
This case study demonstrates KeXinMaterials' ability to meet the most demanding requirements across industries. The same engineering rigor applies across all our 75+ case studies. For similar projects, contact us at kexin@beeaa.com for a 12h custom quote.